Balaji Tamarappoo1, Donghee Han2, Jeffrey Tyler3, Tarun Chakravarty3, Yuka Otaki2, Robert Miller2, Evann Eisenberg2, Siddharth Singh3, Takahiro Shiota3, Robert Siegel3, Jasminka Stegic3, Tracy Salseth3, Wen Cheng3, Damini Dey4, Louise Thomson2, Daniel Berman5, John Friedman2, Raj Makkar1. 1. Smidt Heart Institute, Cedars Sinai Medical Center, Los Angeles, California, USA; Mark Taper Imaging Institute, Cedars Sinai Medical Center Los Angeles, California, USA. 2. Mark Taper Imaging Institute, Cedars Sinai Medical Center Los Angeles, California, USA. 3. Smidt Heart Institute, Cedars Sinai Medical Center, Los Angeles, California, USA. 4. Mark Taper Imaging Institute, Cedars Sinai Medical Center Los Angeles, California, USA; Biomedical Imaging Research Institute, Cedars Sinai Medical Center, Los Angeles, California, USA. 5. Smidt Heart Institute, Cedars Sinai Medical Center, Los Angeles, California, USA; Mark Taper Imaging Institute, Cedars Sinai Medical Center Los Angeles, California, USA. Electronic address: Daniel.Berman@cshs.org.
Abstract
OBJECTIVES: The association between extracellular volume (ECV) measured by computed tomography angiography (CTA) and clinical outcomes was evaluated in low-flow low-gradient (LFLG) aortic stenosis (AS) patients undergoing transcatheter aortic valve replacement (TAVR). BACKGROUND: Patients with LFLG AS comprise a high-risk group with respect to clinical outcomes. Although ECV, a marker of myocardial fibrosis, is traditionally measured with cardiac magnetic resonance, it can also be measured using cardiac CTA. The authors hypothesized that in LFLG AS, increased ECV may be associated with adverse clinical outcomes. METHODS: In 150 LFLG patients with AS who underwent TAVR, ECV was quantified using pre-TAVR CTA. Echocardiographic and clinical information including all-cause death and heart failure rehospitalization (HFH) was obtained from electronic medical records. A Cox proportional hazards model was used to evaluate the association between ECV and death+HFH. RESULTS: During a median follow-up of 13.9 months (range 0.07 to 28.9 months), there were 31 death+HFH events (21%). Patients who experienced death+HFH had a greater median Society of Thoracic Surgery score (9.9 vs. 4.7; p < 0.01), lower left ventricular ejection fraction (42.3 ± 20.2% vs. 52.7 ± 17.2%; p < 0.01), lower mean transvalvular gradient (24.9 ± 8.9 mm Hg vs. 28.1 ± 7.3 mm Hg; p = 0.04) and increased mean ECV (35.5 ± 9.6% vs. 29.9 ± 8.2%; p < 0.01) compared with patients who did not experience death+HFH. In a multivariable Cox proportional hazards model, increase in ECV was associated with increase in death+HFH, (hazard ratio per 1% increase: 1.04, 95% confidence interval: 1.01 to 1.09; p < 0.01). CONCLUSIONS: In patients with LFLG AS, CTA measured increase in ECV is associated with increased risk of adverse clinical outcomes post-TAVR and may thus serve as a useful noninvasive marker for prognostication.
OBJECTIVES: The association between extracellular volume (ECV) measured by computed tomography angiography (CTA) and clinical outcomes was evaluated in low-flow low-gradient (LFLG) aortic stenosis (AS) patients undergoing transcatheter aortic valve replacement (TAVR). BACKGROUND:Patients with LFLG AS comprise a high-risk group with respect to clinical outcomes. Although ECV, a marker of myocardial fibrosis, is traditionally measured with cardiac magnetic resonance, it can also be measured using cardiac CTA. The authors hypothesized that in LFLG AS, increased ECV may be associated with adverse clinical outcomes. METHODS: In 150 LFLG patients with AS who underwent TAVR, ECV was quantified using pre-TAVR CTA. Echocardiographic and clinical information including all-cause death and heart failure rehospitalization (HFH) was obtained from electronic medical records. A Cox proportional hazards model was used to evaluate the association between ECV and death+HFH. RESULTS: During a median follow-up of 13.9 months (range 0.07 to 28.9 months), there were 31 death+HFH events (21%). Patients who experienced death+HFH had a greater median Society of Thoracic Surgery score (9.9 vs. 4.7; p < 0.01), lower left ventricular ejection fraction (42.3 ± 20.2% vs. 52.7 ± 17.2%; p < 0.01), lower mean transvalvular gradient (24.9 ± 8.9 mm Hg vs. 28.1 ± 7.3 mm Hg; p = 0.04) and increased mean ECV (35.5 ± 9.6% vs. 29.9 ± 8.2%; p < 0.01) compared with patients who did not experience death+HFH. In a multivariable Cox proportional hazards model, increase in ECV was associated with increase in death+HFH, (hazard ratio per 1% increase: 1.04, 95% confidence interval: 1.01 to 1.09; p < 0.01). CONCLUSIONS: In patients with LFLG AS, CTA measured increase in ECV is associated with increased risk of adverse clinical outcomes post-TAVR and may thus serve as a useful noninvasive marker for prognostication.
Authors: Alexander Lauten; Ralf Zahn; Martin Horack; Horst Sievert; Axel Linke; Markus Ferrari; Axel Harnath; Eberhard Grube; Ulrich Gerckens; Karl-Heinz Kuck; Stefan Sack; Jochen Senges; Hans R Figulla Journal: JACC Cardiovasc Interv Date: 2012-05 Impact factor: 11.195
Authors: Clerio F Azevedo; Marcelo Nigri; Maria L Higuchi; Pablo M Pomerantzeff; Guilherme S Spina; Roney O Sampaio; Flávio Tarasoutchi; Max Grinberg; Carlos Eduardo Rochitte Journal: J Am Coll Cardiol Date: 2010-07-20 Impact factor: 24.094
Authors: Daniel S Berman; Nathan D Wong; Heidi Gransar; Romalisa Miranda-Peats; John Dahlbeck; Sean W Hayes; John D Friedman; Xingping Kang; Donna Polk; Rory Hachamovitch; Leslee Shaw; Alan Rozanski Journal: J Am Coll Cardiol Date: 2004-08-18 Impact factor: 24.094
Authors: Frank Weidemann; Sebastian Herrmann; Stefan Störk; Markus Niemann; Stefan Frantz; Volkmar Lange; Meinrad Beer; Stefan Gattenlöhner; Wolfram Voelker; Georg Ertl; Jörg M Strotmann Journal: Circulation Date: 2009-08-03 Impact factor: 29.690
Authors: Marc R Dweck; Sanjiv Joshi; Timothy Murigu; Francisco Alpendurada; Andrew Jabbour; Giovanni Melina; Winston Banya; Ankur Gulati; Isabelle Roussin; Sadaf Raza; Nishant A Prasad; Rick Wage; Cesare Quarto; Emiliano Angeloni; Simone Refice; Mary Sheppard; Stuart A Cook; Philip J Kilner; Dudley J Pennell; David E Newby; Raad H Mohiaddin; John Pepper; Sanjay K Prasad Journal: J Am Coll Cardiol Date: 2011-09-13 Impact factor: 24.094
Authors: Russell J Everett; Lionel Tastet; Marie-Annick Clavel; Calvin W L Chin; Romain Capoulade; Vassilios S Vassiliou; Jacek Kwiecinski; Miquel Gomez; Edwin J R van Beek; Audrey C White; Sanjay K Prasad; Eric Larose; Christopher Tuck; Scott Semple; David E Newby; Philippe Pibarot; Marc R Dweck Journal: Circ Cardiovasc Imaging Date: 2018-06 Impact factor: 7.792
Authors: Paul R Scully; Thomas A Treibel; Marianna Fontana; Guy Lloyd; Michael Mullen; Francesca Pugliese; Neil Hartman; Philip N Hawkins; Leon J Menezes; James C Moon Journal: J Am Coll Cardiol Date: 2018-01-30 Impact factor: 27.203
Authors: Paul R Scully; Kush P Patel; Ernst Klotz; João B Augusto; George D Thornton; Bunny Saberwal; Ulrike Haberland; Simon Kennon; Muhiddin Ozkor; Michael Mullen; Guy Lloyd; Andrew Kelion; Leon J Menezes; Philip N Hawkins; James C Moon; Francesca Pugliese; Thomas A Treibel Journal: JACC Cardiovasc Imaging Date: 2021-12-15